Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.
Jonathan S. Levin, PhD
Advertisement
Articles by Jonathan S. Levin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
2
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
3
Fifth Death Confirmed in NYC Legionnaires' Outbreak
4
When the Oncologist Becomes the PCP: Emily K. Curran, MD
5